An approach for the extract generation and toxicological assessment of tobacco-free 'modern' oral nicotine pouches

An approach for the extract generation and toxicological assessment of tobacco-free 'modern' oral nicotine pouches
复制标题

DOI:
10.1016/j.fct.2020.111713
复制
发表时间:
2020-11-01
影响因子:
4.3
通讯作者:
Gaca, M.
Gaca, M.
中科院分区:
农林科学2区
文献类型:
--
作者:
Bishop, E.;East, N.;Gaca, M.

文献摘要

被引文献

相似文献

不含烟草的“现代”口腔尼古丁烟袋(MOPS),在外观和用途上与瑞典式鼻烟相似,但不含烟草。在本研究中,我们提出了一种简单的方法来提取细胞培养液中的囊状物质,提供了一致的尼古丁浓度和容易的体外评估。用人口腔成纤维细胞(HGF)和人肺上皮细胞(H292)进行了一系列的体外筛选试验(活性、细胞健康标志物、氧化应激和遗传毒性)。从Lyft中提取提取物,并与鼻烟(CRP1.1)和香烟(1R6F)参比产品进行比较,MOP和CRP1.1提取物是通过在20ml细胞培养液中孵育一个袋子产生的,而1R6F AQE是通过在20ml细胞培养液中抽1支香烟得到的。1R6F在大多数试验中显示出毒理学反应;CRP1.1有轻微到中度的作用,而MOP在所有的试验中几乎没有反应。本研究证明了MOPS提取物的产生及其体外筛选毒理学评价方法。未来的产品使用、药代动力学和临床研究将进一步证实MOPS的风险潜力降低。
Tobacco-free 'modern' oral nicotine pouches (MOPs), are similar in appearance and use to Swedish-style snus, but without tobacco. There are few identified methods to create test samples for toxicologically assessment of MOPs in vitro.In this study we present a simple method for the extraction of pouch material in cell culture media, providing consistent nicotine concentration and easy in vitro assessment. A series of contemporary in vitro screening assays (viability, cell health markers, oxidative stress and genotoxicity) using human oral fibroblasts (HGF) and human lung epithelial cells (H292) were employed. Extracts were generated from LYFT and compared to snus (CRP1.1) and cigarette (1R6F) reference products.MOP and CRP1.1 extracts were generated by incubating one pouch in 20 ml of cell culture media, while 1R6F AqE was prepared by smoking 1 cigarette into 20 ml of cell culture media. 1R6F demonstrated toxicological responses in most assays; CRP1.1 had minimal to moderate effects while MOP demonstrated little or no response in all assays.This study demonstrated the generation of MOPs extracts and their toxicological evaluation using in vitro screening approaches. Future product usage, pharmacokinetics and clinical studies will further substantiate the reduced risk potential of MOPs.